Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

The First Trust NYSE Arca Biotechnology ETF (FBT) was launched on 06/19/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.

Zacks Investment Research • May 7, 2026

Medical Technology Stocks: Innovation Endures As Valuations Reset

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Seeking Alpha • May 2, 2026

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund launched on June 19, 2006.

Zacks Investment Research • Apr 30, 2026

Global PMI: Tracking The Sectors Hit Hardest By The Middle East War

Survey data underscored how the war in the Middle East has already had a material impact on economic growth around the world. Drilling down deeper, the data showed weaker growth trends were recorded across all major industries globally.

Seeking Alpha • Apr 12, 2026

Can Forgotten Biotech Break Out?

After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Biotech hasn't garnered much attention lately, with all the coverage of the Iran War and the AI Doom trade that's been taking down software stocks even as AI infrastructure stocks continue to surge.

Seeking Alpha • Apr 11, 2026

Biotech Could Be One of 2026's Biggest Winners, and This ETF Is Perfectly Positioned

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak.

24/7 Wall Street • Jan 9, 2026

2 ETFs to Watch for Outsized Volume on Biotechnology Stocks

Biotech ETFs PBE and FBT saw trading volumes soar to over four times their averages, signaling rising interest amid a down day for major indexes.

Zacks Investment Research • Nov 18, 2025

Investing In Health Stocks - How Policy Clarity Is Opening Doors

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Seeking Alpha • Nov 11, 2025

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Seeking Alpha • May 30, 2025

FBT: This 30-Stock Biotech ETF Isn't Worth The Risk Today

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional returns compared to the broader Health Care sector, despite its high 0.56% expense ratio. A closer look at performance reveals that FBT is subject to periods of significant gains and losses, though it has struggled over the last five and ten-year periods.

Seeking Alpha • May 19, 2025